A persistent HSV gene delivery system
JP2025509025A5Pending Publication Date: 2026-06-18UNIV HOUSTON SYST
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- UNIV HOUSTON SYST
- Filing Date
- 2023-03-15
- Publication Date
- 2026-06-18
AI Technical Summary
Technical Problem
Existing HSV gene delivery vectors are easily neutralized and cleared in the host's immune system in the body, resulting in inefficient delivery.
Method used
By conducting multiple contacts of the HSV gene delivery vector with immune serum containing high levels of anti-HSV antibodies, mutating neutralizing epitopes on glycoprotein B and glycoprotein D and inserting exogenous CD47 domains into membrane casein to improve vector resistance.
Benefits of technology
It significantly improves the resistance of HSV gene delivery vectors, extends its existence time in vivo, and improves its resistance to antibodies and NK cells.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
The present invention relates to herpes simplex virus (HSV)-based vectors for delivering transgenes (e.g., therapeutic genes) that are more resistant to neutralization by the immune system, phagocytosis, and NK cells, as well as methods for their preparation and use to treat disorders and diseases (such as those associated with gene expression). In one embodiment, the HSV vectors are prepared by treatment with immune serum containing high levels of anti-HSV antibodies. The HSV vectors may include an extracellular CD47 domain inserted at the N-terminus of the glycoprotein to inhibit phagocytic activity, and the absence of gE to avoid NK cells.
Need to check novelty before this filing date? Find Prior Art